Journal of Molecular and Cellular Biochemistry

Predictive, cellular, or symbolic biomarkers that pass validation can serve as a predictor of clinical outcomes. Predictive biomarkers are used to help good therapy, and they often indicate the potential benefit of a particular treatment. For example, biomarkers of molecules are built into the presentation of the design of a particular molecule process and the drug's promising mechanism to capture features that allow the assessment of the individual therapeutic response. This provides a two-dimensional approach to both observable and retrospective studies and is used by biomarkers to predict outcomes. For example, in metastatic colorectal cancer predictive biomarkers can be as a way of assessing and improving patients' survival rates and in each case, they can serve as a means of saving patients from unnecessary pain from cancer treatment programs.

Typical examples of prediction of biomarkers are genes such as ER, PR and HER2 / neu in breast cancer, BCR-ABL fusion protein in chronic myeloid leukemia, c-KIT changes in GIST tumors and EGFR1 mutations in NSCLC.